Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03874884 2025-05-14

LuPARP

Phase 1 Active not recruiting

70 enrolled

Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT03532880 2025-02-07

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Phase 1 Completed

26 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05358639 2024-11-18

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

Phase 1 Active not recruiting

36 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02338622 2024-09-26

ComPAKT

Phase 1 Completed

60 enrolled

Advanced Cancer

NCT02308072 2024-05-08

ORCA-2

Phase 1 Active not recruiting

70 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02229656 2023-11-07

Olaparib and Radiotherapy in Head and Neck Cancer

Phase 1 Unknown

12 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms

NCT03924245 2022-04-04

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Phase 1 Terminated

3 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03057145 2021-09-02

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

Phase 1 Completed

29 enrolled

Other solid neoplasm

Solid Tumor

NCT02227082 2021-08-04

Olaparib and Radiotherapy in Inoperable Breast Cancer

Phase 1 Completed

7 enrolled

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01623349 2021-02-10

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Phase 1 Completed

118 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Recurrence

NCT03544125 2020-11-20

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Phase 1 Completed

3 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02121990 2020-08-21

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Phase 1 Completed

17 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02686008 2020-01-13

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Phase 1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03575078 2019-09-25

ARQ761 + PARP Inhibitor in Refractory Solid Tumors

Phase 1 Withdrawn

Lymphoid

Lymphoma

NCT01758731 2019-09-23

Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History

Phase 1 Completed

17 enrolled 8 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Smoking

NCT02324998 2019-08-29

CaNCaP03

Phase 1 Completed

20 enrolled

Genitourinary

Prostatic Neoplasms

NCT02418624 2019-01-16

REVIVAL

Phase 1 Completed

25 enrolled

BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

NCT01390571 2018-02-05

Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma

Phase 1 Completed

34 enrolled

CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT01296763 2016-03-22

Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

Phase 1 Completed

18 enrolled 12 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01460888 2013-08-19

ROCOCO

Phase 1 Unknown

36 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT01491139 2012-05-30

ORCA

Phase 1 Withdrawn

Tumor-Agnostic

Carcinoma, Squamous Cell

Clinical Trials

Selumetinib and Olaparib in Solid Tumors

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

RADIOSARP

Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

CONCORDE

RadioPARP

PHOEBE

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

LumOnate

PRRT-PARPi

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

LuPARP

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

ComPAKT

ORCA-2

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Olaparib and Radiotherapy in Head and Neck Cancer

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

Olaparib and Radiotherapy in Inoperable Breast Cancer

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

ARQ761 + PARP Inhibitor in Refractory Solid Tumors

Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History

CaNCaP03

REVIVAL

Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma

Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

ROCOCO

ORCA